Patients with lung adenocarcinoma typically carry a mutation in the Epidermal Growth Factor Receptor (EGFR) gene, making them ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Patients with this particular type of lung cancer carry a specific mutation in the Epidermal Growth Receptor Factor (EGFR) ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

This surge reflects the increasing reliance on genetic diagnostics for identifying hereditary diseases, guiding cancer ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...